This antibody was raised against full-length human p73. The epitope is thought to lie around the center of the molecule (NP_005418).
It reacts with alpha, beta, gamma and delta isoforms of mouse and human p73 as well as the dominant negative p73 (Costanzo, et al, 2002). Because of its reactivity pattern it may be regarded as anti-pan p73. Immunoprecipitation details can be found in Sayan et al (2005). NB100-56674 has been shown to recongize all the known alternative splicing variants of human and mouse p73 (Costanzo et al, 2002). The antibody does not cross react with p53.
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Reported use for Chromatin Immunoprecipitation assay (See accardi et al); Immunocytochemistry/Immunofluorescence and Immunoprecipitation (see Sayan et al). Use in Immunohistochemistry reported in scientific literature (PMID 19816568) The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publications using NB100-56674 in the following applications:
The clone has also been referred to as 1288 in the literature. Endogenous expression of p73 has been detected in a variety of cell types; please refer to Product Citations for details regarding culture and treatment conditions.
Alternate Names for p73 Antibody (5B1288)
P73p53-like transcription factor
tumor protein p73
p73 was identified as a long-lost cousin of tumor suppressor protein, p53. p73 has high homology with p53 as well as with p63, a gene implicated in the maintenance of epithelial stem cells. Significant homology between p53, p63, and p73 (approximately 63% amino acid identity in the DNA-binding domain suggest that they may have overlapping functions in the regulation of gene expression. The targeted disruption of p73 gene leads to defects hippocampal dysgenesis, hydrocephalus, chronic inflammation and infections. Recently, spilicing variant mRNAs of p73 has been identified in MCF-7, a breast carcinoma cell line. These mRNAs code for variant p73 proteins bearing distinct carboxy-terminal structures suggesting that the carboxy-terminal region of p73 may be important for the functions of this protein. Tumor BioMarker: Vella et al (2003) found p73 to be upregulated in a significant fraction of anaplastic thyroid cancers, whereas p73 was not detectable in normal thyroid epithelial cells nor in papillary or follicular thyroid cancer.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.